Ocuphire Pharma (OCUP) has a P/E ratio of -3.66, below the Healthcare sector average of 19.01.
Get informed when a big investor buys or sells
+ Follow-3.66
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Ocuphire Pharma (OCUP) currently reports a P/E ratio of -3.66. That is below the Healthcare sector average of 19.01. Use the charts on this page to explore Ocuphire Pharma's P/E ratio history and peer comparisons.
Ocuphire Pharma's P/E ratio of -3.66 is lower than the Healthcare sector average of 19.01. That is roughly 119.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Ocuphire Pharma's market price to a fundamental measure such as earnings, sales, or book value. At -3.66, OCUP can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -3.66, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.01. From there, open related valuation or income-statement pages for Ocuphire Pharma, and consider following OCUP for alerts when major investors trade the stock.
Ocuphire Pharma is classified in the Healthcare sector. On P/E ratio, it currently shows -3.66 versus a sector average near 19.01. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OCUP with unrelated industries.